Is Cyclophosphamide safe for dogs and cats?
High risk for petsCyclophosphamide is used in veterinary oncology, primarily in combination protocols for canine lymphoma (CHOP-based: cyclophosphamide, doxorubicin, vincristine, prednisone), mast cell tumors, and other neoplasias. Veterinary use follows similar toxicity management principles as human oncology. The primary veterinary concern specific to cyclophosphamide is sterile hemorrhagic cystitis — clinically significant in dogs at cumulative doses and in those not receiving adequate hydration post-administration. Mesna is used in veterinary settings for high-dose cyclophosphamide protocols; furosemide and forced diuresis are also used. Myelosuppression with neutrophil nadir at approximately days 7–10 is dose-limiting; CBC monitoring is standard. Accidental ingestion of cyclophosphamide tablets by dogs (from owner prescriptions or spilled medications) is a veterinary emergency requiring immediate decontamination and intensive supportive care monitoring. Cyclophosphamide tablets have a distinctive appearance that may not deter ingestion.
What is cyclophosphamide?
The IUPAC name is N,N-bis(2-chloroethyl)-2-oxo-1,3,2lambda5-oxazaphosphinan-2-amine.
Also known as: N,N-bis(2-chloroethyl)-2-oxo-1,3,2lambda5-oxazaphosphinan-2-amine, Cytoxan, Cyclophosphamid, Cyclophosphane.
- IUPAC name
- N,N-bis(2-chloroethyl)-2-oxo-1,3,2lambda5-oxazaphosphinan-2-amine
- CAS number
- 50-18-0
- Molecular formula
- C7H15Cl2N2O2P
- Molecular weight
- 261.08 g/mol
- SMILES
- C1CNP(=O)(OC1)N(CCCl)CCCl
- PubChem CID
- 2907
Risk for dogs
High riskCyclophosphamide is used in veterinary oncology, primarily in combination protocols for canine lymphoma (CHOP-based: cyclophosphamide, doxorubicin, vincristine, prednisone), mast cell tumors, and other neoplasias. Veterinary use follows similar toxicity management principles as human oncology. The primary veterinary concern specific to cyclophosphamide is sterile hemorrhagic cystitis — clinically significant in dogs at cumulative doses and in those not receiving adequate hydration post-administration. Mesna is used in veterinary settings for high-dose cyclophosphamide protocols; furosemide and forced diuresis are also used. Myelosuppression with neutrophil nadir at approximately days 7–10 is dose-limiting; CBC monitoring is standard. Accidental ingestion of cyclophosphamide tablets by dogs (from owner prescriptions or spilled medications) is a veterinary emergency requiring immediate decontamination and intensive supportive care monitoring. Cyclophosphamide tablets have a distinctive appearance that may not deter ingestion.
Risk for cats
High riskCyclophosphamide is used in feline oncology for lymphoma and other malignancies, typically at lower doses than dogs and at less frequent intervals due to enhanced sensitivity. Cats tolerate cyclophosphamide reasonably well at appropriately selected doses under veterinary oncologist supervision. Hemorrhagic cystitis is less commonly reported in cats than in dogs but remains a risk. Myelosuppression is the primary concern; cats may develop more pronounced leukopenia than dogs at equivalent mg/kg doses. Accidental ingestion by cats of human cyclophosphamide tablets or IV solution residue is a veterinary emergency. Clinical management focuses on early decontamination, hydration for urothelial protection, and monitoring of CBC during the myelosuppression nadir period.
Regulatory consensus
6 regulatory and scientific bodies have classified Cyclophosphamide. The classifications differ — that's the data.
| Agency | Year | Classification | Notes |
|---|---|---|---|
| IARC | 2012 | Group 1 | IARC Group 1 classification for cyclophosphamide based on sufficient evidence of carcinogenicity in humans — specifically, increased incidence of bladder cancer, myelodysplastic syndrome (MDS), and acute myeloid leukemia (AML) in patients treated with cyclophosphamide as part of cancer chemotherapy or immunosuppressive therapy. Acrolein, a reactive metabolite of cyclophosphamide, is the primary causative agent for bladder urothelial toxicity and carcinogenicity. Mesna (sodium 2-mercaptoethane sulfonate) co-administration is used clinically to inactivate acrolein in the bladder and reduce hemorrhagic cystitis and bladder cancer risk. |
| EPA CTX / NTP RoC | — | Known Human Carcinogen | |
| EPA CTX / IARC | — | Group 1 - Carcinogenic to humans | |
| EPA CTX / CalEPA | — | Known human carcinogen | |
| EPA CTX / Genetox | — | Genotoxicity: positive (Ames: positive, 50 positive / 1 negative reports) | |
| EPA CTX / Genetox | — | Genotoxicity: positive (Ames: positive, 50 positive / 1 negative reports) |
Regulators apply different standards of evidence — animal-data weighting, exposure-pattern assumptions, epidemiological power thresholds — which is why two scientific bodies can review the same data and reach different conclusions. The disagreement is the data.
Where pets encounter cyclophosphamide
- Industrial Facilities — Manufacturing plants, Chemical storage areas, Waste treatment sites
- Occupational Environments — Factories, Warehouses, Transportation vehicles
Safer alternatives
Lower-risk approaches that achieve a similar outcome to Cyclophosphamide:
-
Alternative drug class; Non-pharmacological therapy; Lowest effective dose
Trade-offs: Direct chemical substitution requires verification that the replacement does not introduce new hazards (regrettable substitution). Conduct full hazard assessment of proposed alternative before adoption.Relative cost: 1.2-2×
Frequently asked questions
Is cyclophosphamide safe for pets?
Cyclophosphamide is used in veterinary oncology, primarily in combination protocols for canine lymphoma (CHOP-based: cyclophosphamide, doxorubicin, vincristine, prednisone), mast cell tumors, and other neoplasias. Veterinary use follows similar toxicity management principles as human oncology. The primary veterinary concern specific to cyclophosphamide is sterile hemorrhagic cystitis — clinically significant in dogs at cumulative doses and in those not receiving adequate hydration post-administration. Mesna is used in veterinary settings for high-dose cyclophosphamide protocols; furosemide and forced diuresis are also used. Myelosuppression with neutrophil nadir at approximately days 7–10 is dose-limiting; CBC monitoring is standard. Accidental ingestion of cyclophosphamide tablets by dogs (from owner prescriptions or spilled medications) is a veterinary emergency requiring immediate decontamination and intensive supportive care monitoring. Cyclophosphamide tablets have a distinctive appearance that may not deter ingestion.
What products contain cyclophosphamide?
Cyclophosphamide appears in: Manufacturing plants (Industrial facilities); Chemical storage areas (Industrial facilities); Factories (Occupational environments); Warehouses (Occupational environments).
Why do regulators disagree about cyclophosphamide?
Cyclophosphamide has been classified by 6 agencies including IARC, EPA CTX / NTP RoC, EPA CTX / IARC, EPA CTX / CalEPA, EPA CTX / Genetox, with differing conclusions. Regulators apply different standards of evidence (animal data weighting, exposure-pattern assumptions, epidemiological power thresholds), which is why two scientific bodies can review the same data and reach different conclusions. See the regulatory consensus table on this page for the full picture.
See Cyclophosphamide in the pets app
Look up products containing cyclophosphamide, compare to alternatives, and explore the full data record.
Open in pets View raw API dataSources (5)
- IARC Monographs Volume 100A: Pharmaceuticals — Cyclophosphamide, Group 1 Classification (Bladder Cancer, AML/MDS; Acrolein Mechanism) (2012) — regulatory
- US FDA: Cyclophosphamide Prescribing Information — Indications, Dosing, Myelosuppression, Hemorrhagic Cystitis, Teratogenicity, and Secondary Malignancy Warnings (2021) — regulatory
- ASPCA Animal Poison Control Center: Cyclophosphamide and Alkylating Agent Toxicosis in Dogs and Cats — Emergency Management (2023) — veterinary
- Plumb's Veterinary Drug Handbook (10th ed.) — Cyclophosphamide: Veterinary Oncology Use, CHOP Protocol, Hemorrhagic Cystitis Prevention, and Toxicity Management (2023) — veterinary
- NIOSH: Safe Handling of Hazardous Drugs — Antineoplastic Agents, PPE Requirements, Engineering Controls, and Pharmaceutical Waste Disposal (2016) — regulatory
Reference data, not professional advice. Aggregates publicly available regulatory and scientific data; not a substitute for veterinary, medical, legal, or regulatory advice. Why we built ALETHEIA →